Rohto Pharmaceutical raises FY2027 operating profit forecast to JPY 45,000 million

• Rohto raised its FY ending March 31, 2027 consolidated forecast, citing stronger-than-expected Q1 performance in Asia, Japan, Europe.
• Net sales outlook lifted to JPY 372,300 million from JPY 369,500 million; operating income seen at JPY 45,000 million from JPY 43,800 million.
• Ordinary income forecast increased to JPY 47,400 million from JPY 46,100 million; profit attributable to owners of parent to JPY 35,200 million from JPY 34,500 million.
• Assumed exchange rates revised to JPY 158 per $1 from JPY 155; to JPY 23 per yuan from JPY 22.
• Forecast implies gains versus FY ended March 31, 2026 net sales JPY 343,725 million; operating income JPY 41,118 million; profit attributable JPY 34,247 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rohto Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.